Sep 11,2018

On a mission to eradicate chronic disease: Interview with Stephanie Tilenius, Founder and CEO of Vida Health

Vida Health’s CEO Stephanie Tilenius is not afraid to dream big. After many successful years at Google, PayPal, eBay and KPCB, she’s now working to wipe out chronic disease by placing personal healthcare in the pocket of the consumer. An Interview with Stephanie Tilenius, Founder and CEO of Vida Health.

View Analyst & Ambassador Comments
Go to original news
Sep 11,2018

One Drop Exclusive: One Drop Blood Glucose Monitoring System Now Connects to Apple Watch

One Drop expands their industry leading Apple Watch diabetes management solution by offering the first and only wireless blood glucose monitoring system to connect directly to Apple Watch.

COLLABORATION PARTNERSHIP

#connected device

#bgm

View Analyst & Ambassador Comments
Go to original news
Sep 12,2018

Tandem Diabetes Care to Webcast Investor & Analyst Day on September 25, 2018

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced it will host an Institutional Investor and Analyst Day from 8:30am to 1:00pm Pacific Time on Tuesday, September 25, 2018 in San Diego, California. The program will include presentations regarding the Company’s longer-term vision, product pipeline, and international expansion. In addition, presentations will be given by clinical and industry experts on the subject of automated insulin delivery (AID). The Company will also host a healthcare provider and patient panel, provide product demonstrations, and will offer tours of its new manufacturing facility.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 12,2018

Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial

The interim results consisted of 25 patients, split approximately equally between Type I and Type II diabetics. 9,371 data points were analysed in total, consisting of 4,630 and 4,741 paired data points analysed using 1-point and 2-point calibration respectively. The MARD (Mean Absolute Relative Deviation, @ 30%/30mg/dL) for the 1-point calibration was 12.19% (80% of all data), and for the 2-point calibration the MARD was 10.65% (88% of all data)). The results are in line with the company’s expectations, and compare favorably with competitor products.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 14,2018

DarioHealth Closes on $10,345,000 Through Private Placement Offering

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it has closed on a private placement offering with institutional and private investors for the sale of shares of the Company's common stock and shares of the Company's newly designated Series D convertible preferred stock. As a part of this private placement, which raised $10,345,000 in the aggregate before expenses and placement agent fees, the Company issued 4,266,800 shares of common stock at a price per share of $0.90.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Sep 18,2018

Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, today announced that it has signed a non-binding letter of intent for an exclusive licensing agreement with Al-Danah Medical Co for the commercial launch of sugarBEAT® in Qatar. A final binding license agreement between Nemaura and Al-Danah is scheduled for completion by November 16, 2018 in readiness for anticipated 2019 Qatar product launch.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 19,2018

The Actiste companion applications and The Benefit Loop are now CE certified.

The mobile applications and digital infrastructure of Brighter's award-winning service for insulin treated diabetics – Actiste® Diabetes Management as a Service – are now CE certified. The applications are offered exclusively to Actiste subscribers. Through The Benefit Loop, Actiste connects all relevant parties in the care chain; the patient receives support and guidance, relatives can monitor and the caregivers can adapt and improve.

REGULATORY CE MARK

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 20,2018

DarioHealth to Host Investor Conference Call on October 4, 2018

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will host a conference call to provide a business update for investors at 9:00am EDT on Thursday, October 4, 2018. The conference call will be hosted by Erez Raphael, Chief Executive Officer, Olivier Jarry, President and Chief Commercial Officer, Zvi Ben-David, Chief Financial Officer, and Yoav Shaked, Chairman of the Board.

View Analyst & Ambassador Comments
Go to original news
Sep 20,2018

First-Half 2018 of Voluntis: Expanded and strengthened abilities to pursue future growth

Voluntis (Euronext Paris, ticker: VTX – ISIN: FR0004183960), a digital biotech specialized in digital therapeutics, announces its revenue and results for the first half of 2018, closed as of 30 June 2018. Voluntis reported first-half revenue of €2.2 million versus €5.7 million in first-half 2017, which benefited from €3.5 million of milestone payments compared with €0.1 million this year.

View Analyst & Ambassador Comments
Go to original news
Sep 24,2018

Insulet to Announce Third Quarter 2018 Financial Results on November 1, 2018

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2018 on November 1, 2018 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES